Results 191 to 200 of about 16,303 (230)

The Relevance of Factor VIII (FVIII) Pharmacokinetics to TDM and Hemophilia A Treatment: Is B Domain–Deleted FVIII Equivalent to Full-Length FVIII?

Therapeutic Drug Monitoring, 2012
Recombinant DNA-derived clotting factor VIII concentrates (rFVIII) potentially have safety advantages over plasma-derived products. Removal of the B domain of the FVIII molecule does not seem to reduce the procoagulant activity and improve the efficiency of the manufacturer.
openaire   +2 more sources

FVIII administration in surgery

Haemophilia, 2011
B, Ewenstein, W Y, Wong, K, Casey, M, Alai   +3 more
openaire   +2 more sources

FVIII

2009
Robert J. Desnick, Orlando Guntinas-Lichius, George W. Padberg, Gustav Schonfeld, Xiaobo Lin, Maurizio Averna, Pin Yue, John-John B. Schnog, Victor E. A. Gerdes, Pedro R. Cutillas, Robert J. Unwin, Heike Schulze, Konrad Sandhoff, Jean-François Pellissier, Georges Serratrice, Dominique Figarella-Branger, Cord Sunderkötter, Marcelo Gustavo Binker, Laura Iris Cosen-Binker, Matthias Wettstein, Peter von den Driesch, Rima Nabbout, Massimo Mantegazza, Olivier Dulac, Johann Michael Schröder, Ho Sung Kang, Johann Michael Schröder, Marina Marchetti Hugo Ten Cate, Marina Marchetti, Hugo ten Cate, Lev I. Patrushev, Lee S. Weinstein, Adiba Isa, Fernando Azpiroz, Guang-Sheng Li, Ling Jing, Hui Xu, Anne M. Molloy, John M. Scott, Cord Sunderkötter, Axel Lorentz, Stephan C. Bischoff, Filippo Tamanini, Filippo Tamanini, Thomas Klockgether, Derek A. Wong, Jürgen Kopitz, Carolina von Reitzenstein, Michael Cantz   +48 more
openaire   +1 more source

FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis

Drug Discovery Today, 2022
Dominique Heymann, Marc Fouassier, Javier Munoz-Garcia   +2 more
exaly  

Characterization of FVIII Pharmacokinetics in Hemophilia A Patients with or without Nonneutralizing FVIII Antibodies

Hämostaseologie, 2020
Stephan Schultze-Strasser, Diana Stichel, Aleksander Orlowski, Esra Kaya, Christoph Königs, Christine Heller   +5 more
openaire   +1 more source

Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII

Blood, 2022
Edward Tuddenham, Richard Wolf-Garraway, Gavin Ling   +2 more
openaire   +1 more source

Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis

Journal of Thrombosis and Haemostasis, 2005
Saskia Middeldorp, Harry Büller, K Hamulyák   +2 more
exaly  

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A

Haemophilia, 2015
Christine Mannhalter, Michael Schemper, P Quehenberger   +2 more
exaly  

Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study

Haemophilia, 2017
Steve Kitchen, Annette Bowyer
exaly  

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements

Haemophilia, 2014
Yesim Dargaud, C Negrier, M Fretigny
exaly